NYSE: CRL · Diagnostics & Research
Charles River Laboratories International (CRL) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Charles River Laboratories International (CRL) at $423.73 a share. The stock last closed at $335.52, which puts the model's fair value 26.3% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Charles River Laboratories International, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $429.83 to $423.73 (-1.4%). The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move.
What the model makes of itThe price of $335.52 is 26.3% below it: Undervalued, on a high evidence grade.
What's nextNext report on 17 Feb 2027. Options prices imply a move of about 14% either way over the next month. On the model's Scorecard Leaders list since 13 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CRL?
The calibrated range for CRL over 63 trading days is $285.45 to $397.60. It sits around the last close, and its width comes from the volatility that CRL's own options imply (49% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $313.04 to $564.50. In 73% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Charles River Laboratories International, Inc. (CRL) operates as a contract research organization (CRO). It provides essential preclinical services to the pharmaceutical and biotechnology industries.
Faircurve's model put the fair value at $423.73 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $429.83, so the fair value moved -1.4%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $289.37 to $397.83. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High, which looks at input completeness, comparable companies and their agreement, and the spread of outcomes. It does not say whether the fair value is right.
Charles River scores 48 out of 100 on the model's overall quality measure, against comparable companies. Earnings quality is the strongest factor at 93, with FCF / net income of 9.94x against a peer median of 1.45x. The balance sheet scores 12, with net debt / EBITDA of 9.03x against a peer median of 0.78x. The model compares the company with Revvity, Medpace, Quest Diagnostics, Illumina, Mettler-Toledo, RadNet and IQVIA.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CRL report earnings, and how has the stock reacted?
Charles River Laboratories International's next earnings report is scheduled for 17 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 11.4% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. CRL's 30 day implied volatility works out to about 14.1% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CRL's last 8 reports, ignoring direction, was 7.8%.
What the options market has priced for a month's move in CRL
How does CRL score on business quality?
Charles River Laboratories International's overall quality score is 48 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 50 | 6.2%ROIC | 5.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 93 | 9.94xFCF / net income | 1.45x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 22 | -0.9%Revenue growth, trailing | 3.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 33 | 2.0%Net buybacks / market value | 2.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 12 | 9.03xNet debt / EBITDA | 0.78x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 58 | 4.7 ptsEBITDA margin downside volatility, 5y | 5.6 pts |
How does CRL compare with similar companies?
The companies in diagnostics & research closest to Charles River Laboratories International in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RVTY Revvity, Inc. | $148.85 | $185.05 | +24.3% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
| ILMN Illumina, Inc. | $198.00 | $172.96 | -12.6% | Fairly valued |
| MTD Mettler-Toledo International Inc. | $1,727.26 | $1,679.36 | -2.8% | Fairly valued |
| RDNT RadNet, Inc. | $76.89 | $72.24 | -6.0% | Fairly valued |
| IQV IQVIA Holdings Inc. | $264.73 | $335.69 | +26.8% | Undervalued |
What the comparable companies' multiples alone would give for CRL, the peer-implied price, is $532.24 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
Charles River Laboratories International at a glance
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries.
- Market value
- $16.2B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $4.0B
- Consensus revenue growth, next fiscal year
- -1.7%
- Analysts with estimates
- 9
- Beta to the US market
- 1.26
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CRL was among them.
How the fair value is worked out: the model prices Charles River Laboratories International on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CRL was $429.83. As of 14 Nov 2026 it is $423.73, a change of -1.4%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Charles River Laboratories International's valuation
Is Charles River Laboratories International stock undervalued or overvalued?
On Faircurve's model, CRL reads as Undervalued as of 14 Nov 2026. The model's fair value is $423.73 a share against a last close of $335.52, a gap of +26.3%.
What is CRL's fair value?
$423.73 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $313.04 to $564.50.
What price range does the model give CRL?
$285.45 to $397.60 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Charles River Laboratories International report earnings next?
The next report is scheduled for 17 Feb 2027. Companies can move their dates.
How much has CRL moved on past earnings reports?
Across its last 8 reports the median two session move was 7.8%, ignoring direction. The largest was +22.5% around the report of 7 May 2025.
How confident is the model in this valuation?
The model's evidence grade for CRL is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CRL
The model has an idea open on CRL under Scorecard Leaders since 13 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CRL with their outcomes. A free account is enough.